Available company data, source links and archived checks for Boston Scientific. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Quarter ended 2026-06-30 · consolidated · Company filing
| Quarter | Revenue / income | YoY | Profit | YoY | Net margin | Source |
|---|---|---|---|---|---|---|
| Jun 2026 | Revenue: $5.4 bn | +7.5% | Net profit: $905 mn | +13.8% | 16.6% | Company filing source |
| Mar 2026 | Revenue: $5.2 bn | +11.6% | Net profit: $1.3 bn | +99.3% | 25.7% | Company filing source |
| Dec 2025 | Revenue: $5.3 bn | +15.8% | Net profit: $670 mn | +19.0% | 12.7% | Company filing source |
| Sep 2025 | Revenue: $5.1 bn | +20.3% | Net profit: $755 mn | +61.3% | 14.9% | Company filing source |
| Jun 2025 | Revenue: $5.1 bn | +22.8% | Net profit: $795 mn | +146.9% | 15.7% | Company filing source |
| Mar 2025 | Revenue: $4.7 bn | +20.9% | Net profit: $672 mn | +36.3% | 14.4% | Company filing source |
YoY means change from the same quarter a year earlier. — means no comparable figure is available. Older entries with incomplete source details have not been revalidated under the current checks.
(2)These charges are primarily recorded within Cost of products sold, SG&A Expenses and R&D Expenses.
38
The following table presents our restructuring reserve balance:
Column boundaries are incomplete. Use the source document to interpret these figures.
| | | | | | | | | | | | | | As of December 31, | (in millions) | 2025 | | 2024 | Restructuring reserve balance | $ | 59 | | | $ | 26 |
Litigation-related Net Charges (Credits)
We record certain legal charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) within our consolidated financial statements. We recorded litigation-related net charges of $194 million in 2025 related to the resolution of a legacy IP-related matter related to an acquired company. We did not record any litigation-related net charges (credits) in 2024. All other legal charges, credits and costs are recorded within SG&A expenses.
We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with the financial covenant required by our credit arrangements. Refer to Note I – Commitments and Contingencies to our consolidated financial statements included in Part II, Item 8. Financial Statements and Supplementary Data of this Annual Report for additional discussion of our material legal proceedings.
A growing number of countries have instituted or are contemplating regional or national tender processes driven primarily by price.
A note states amounts recorded to Treasury stock include excise tax on share repurchases.
Acquired identifiable intangible assets, including in-process research and development, are valued using management's best estimates of market-participant inputs; excess purchase price over net tangible and identifiable intangibles is allocated to goodwill.
Acquisition/divestiture-related items are described as highly variable and not representative of ongoing operations.
Keep its available filings, dated fact checks and disclosure alerts together. Your saved country sets your market and its research schedule.
Start free — first week on us →Company data and archived claim checks are shown with available sources. Check the source and date before relying on a figure. This is not investment advice or a recommendation. Investment in securities markets is subject to market risks. Research on this site is produced with substantial use of AI. Terms, disclosures and grievances